Sphene Capital Reaffirms 'Buy' Rating for Vidac Pharma Holding

Sphene Capital GmbH has released an update report on Vidac Pharma Holding Plc, maintaining its 'Buy' rating with a target price of EUR 4.90. The report, published on July 29, 2024, cites promising data from a recent study involving Vidac Pharma's active ingredient, VDA-1275. This compound demonstrated significant efficacy in various mouse and human models of solid tumors.

The study findings reveal that VDA-1275, in development as a systemic drug for treating solid tumors, was effective both as a monotherapy and in combination with standard cancer therapies. Additionally, it elicited an immunological response. The target price is projected based on a three-stage discounted cash flow model, assuming approval for Vidac Pharma's core product, VDA-1102-AK. Monte Carlo scenario values estimate share prices ranging between EUR 4.04 and EUR 5.40.